The aim is to clinically validate the clinical efficacy, usability, and safety of home-based upper limb rehabilitation training using the Neofect Smart Board by comparing the effects between a group using the home-based Neofect Smart Board and a group performing conventional home-based occupational therapy in patients with upper limb dysfunction in the late subacute and chronic stages of neurological diseases.
Patients with neurological diseases aged 19 to 85 years old
Patients with hemiparesis lasting for more than 3 months due to neurological diseases (stroke, traumatic brain injury, brain tumor) and impaired upper limb function
Patients with shoulder flexor and adductor muscle strength of MRC grade 2 or higher
Patients with shoulder extensor and abductor spasticity of MAS grade 1+ or lower
pre-existing significant neurogenic disorders
major psychiatric disorders such as schizophrenia, bipolar disorder, or dementia
History of diseases that caused pain or muscle atrophy in the affected upper limb before the onset of the neurological disease, which interfered with rehabilitation
Severe spasticity of the affected upper limb (Modified Ashworth Scale score ≥3)
Parallel
Home-based Neofect Smart board
Devicea total of 20 sessions of home-based upper limb rehabilitation training using the Neofect Smart board, with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
home-based occupational therapy
Other interventiona total of 20 sessions of home-based upper limb rehabilitation training using the workbook provided by the research team , with 30 minutes per session, 1 session per day, 5 days a week, for 4 weeeks.
Improvement of uper limb score in Fugl-Meyer assessment
(upper limb motor score in Fugl-Meyer assessment at post-intervention) - (upper limb motor score in Fugl-Meyer assessment at baseline) Higher scores mean a better outcome
Click on the lead sponsor to view all of their trials.
